INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $110,763 | -40.8% | 26,372 | -21.5% | 0.00% | – |
Q2 2023 | $187,069 | +68.7% | 33,585 | +73.5% | 0.00% | – |
Q1 2023 | $110,909 | +703.5% | 19,356 | +47.2% | 0.00% | – |
Q4 2022 | $13,803 | -76.6% | 13,146 | -41.0% | 0.00% | – |
Q3 2022 | $59,000 | -70.1% | 22,284 | -45.9% | 0.00% | – |
Q2 2022 | $197,000 | +207.8% | 41,174 | +158.4% | 0.00% | – |
Q1 2022 | $64,000 | -51.9% | 15,937 | -18.0% | 0.00% | – |
Q4 2021 | $133,000 | -36.4% | 19,440 | +8.0% | 0.00% | – |
Q3 2021 | $209,000 | -71.3% | 17,994 | -57.9% | 0.00% | – |
Q2 2021 | $728,000 | +49.8% | 42,754 | +74.2% | 0.00% | – |
Q1 2021 | $486,000 | +20.0% | 24,550 | +24.9% | 0.00% | – |
Q4 2020 | $405,000 | +1127.3% | 19,653 | +1471.0% | 0.00% | – |
Q3 2020 | $33,000 | – | 1,251 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $27,113,000 | 10.69% |
Burrage Capital Management LLC | 242,517 | $4,132,000 | 4.14% |
CHI Advisors LLC | 927,264 | $15,801,000 | 3.68% |
Sofinnova Investments, Inc. | 2,028,308 | $34,562,000 | 1.99% |
Novo Holdings A/S | 1,867,706 | $31,826,000 | 1.41% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,178,985 | $37,130,000 | 0.66% |
RA Capital Management | 2,003,653 | $34,142,000 | 0.55% |
NEA Management Company, LLC | 2,444,379 | $41,652,000 | 0.54% |
Rock Springs Capital Management LP | 840,272 | $14,318,000 | 0.28% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 365,172 | $6,223,000 | 0.09% |